Algenex — Series B · €7.4M

Algenex is a biotech company with production facilities in Tres Cantos. It raised a €7.4M private round led by MasterLux (advised by Cleon Capital and Vita Advisory), and Columbus Life Science Fund II came in as a new investor. The money goes to its CrisBio baculovirus platform for human-health projects, EMA approval of its first veterinary vaccine and its GMP production site. El Referente classified the round as a Series B.

LeadMasterLux RoundSeries B Announced8 Sep 2020 CityTres Cantos · reported Madrid SectorHealthtech & Bio · Biotech Source

Something wrong? Suggest a correction →

The company

Algenex
algenex.com
Acquired by Insud Pharma, 2022

Investors 2

← All funding rounds

Start typing to search across everything.
↑↓ navigate↵ openesc close? shortcuts
Keyboard shortcuts
/ Ctrl K
Search
j k
Next or previous row
↵
Open the row
Ctrl ↵
Open it in a new tab
[ ]
Previous or next page
?
This list